Elad Asher: Higher IPF Is Associated with Adverse Outcomes in ICCU
Elad Asher, Head ICCU at Shaare Zedek Medical Center, Jerusalem, shared a post on X about a recent article he and his colleagues co-authored, published in Thrombosis and Haemostasis, adding:
“Pleased to share our new paper in Thrombosis and Haemostasis.
In an unselected ICCU cohort, higher immature platelet fraction was independently associated with adverse outcomes, supporting IPF as a readily available risk marker.”
Title: Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit
Authors: Elad Asher, Louay Taha, Mohammad Karmi, Akiva Brin, Pierre Sabouret, Mamas A. Mamas, Noam Fink, Ari Naimark, Amjad Abu-Salman, Michael Glikson
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 27, 2026, 11:43Tareq Abadl: Hidden Interferences Behind Unexpected Laboratory Results
-
Oct 27, 2026, 11:42Cece Calhoun: ASH Promotes Clinical Research Training and Mentorship for Emerging Hematologists
-
Oct 27, 2026, 11:41Ifeanyichukwu Ifechidere: The Laboratory Challenges of Measuring Direct Factor Xa Inhibitors
-
Oct 27, 2026, 11:39Gene Therapy Offers New Possibilities for Patients with Thalassaemia in the UAE – Thalassaemia International Federation
-
Oct 27, 2026, 11:35Alan Nurden: rFVIIa Prophylaxis May Reduce Bleeding-Related Healthcare Burden in Glanzmann Thrombasthenia
-
Oct 27, 2026, 10:12Cesar Garrido: WFH Connects with Spanish Thrombosis and Haematology Societies
-
Oct 27, 2026, 10:01Chokri Ben Lamine: CAPS After Autologous SCT – Diagnostic Criteria and Key Mimics
-
Oct 27, 2026, 09:45Jean Terrier: COBRRA Trial – Comparing Bleeding Risks Between DOACs
-
Oct 27, 2026, 08:42Kathleen Freson: SLFN14 at the Crossroads of RNA Regulation, Platelet Biogenesis and Inherited Thrombocytopenia